Concentric Merci Brain Clot Remover Needs Randomized Trial – Panel
This article was originally published in The Gray Sheet
Executive Summary
Stroke patient benefit from Concentric Medical's Merci Retriever embolic retrieval device should be confirmed in a randomized clinical trial, FDA's Neurological Devices Panel recommended Feb. 23 in Gaithersburg, Md
You may also be interested in...
Brain Blood Clot Remover Clears FDA; Comparison Found In Stroke Drug Study
Concentric Medical averted a randomized clinical trial requirement for Merci Retriever by convincing FDA that a single-arm study backs 510(k) clearance of the embolic retrieval system
Brain Blood Clot Remover Clears FDA; Comparison Found In Stroke Drug Study
Concentric Medical averted a randomized clinical trial requirement for Merci Retriever by convincing FDA that a single-arm study backs 510(k) clearance of the embolic retrieval system
Merci Clot Retrieval Catheter Data Show 47% Event-Free Revascularization
Concentric Medical's Merci Retriever embolic retrieval system 510(k) data show a 38% mortality rate in stroke patients versus 27% in the placebo group